Immutep (IMMP) Total Liabilities (2011 - 2026)
Immutep's (IMMP) quarterly Total Liabilities came in at $15.4 million in Q2 2026, up 80.35% on a YoY basis from $8.5 million in Q2 2025, and down 51.39% quarter-over-quarter from $31.7 million in Q4 2025.
Analysis
Immutep (IMMP) Total Liabilities (2011 - 2026) Analysis & Trends
Immutep (IMMP) has reported Total Liabilities for 16 consecutive years, with $15.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Liabilities rose 80.35% year-over-year to $15.4 million; the trailing twelve-month figure through Jun 2026 stood at $15.4 million (up 80.35% YoY), and the FY2026 full-year result was $15.4 million, up 80.35% from the prior year.
- Total Liabilities retreated to $15.4 million in Q2 2026 per IMMP's latest filing, from $31.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $31.7 million in Q4 2025 and bottomed at $5.3 million in Q4 2023.
- Historically, Total Liabilities has averaged $10.5 million across 5 years, with a median of $7.3 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities fell 25.79% in 2022, then surged 392.04% in 2025.
- Over 5 years, Total Liabilities stood at $6.1 million in 2022, then slipped by 13.4% to $5.3 million in 2023, then increased by 21.55% to $6.4 million in 2024, then soared by 392.04% to $31.7 million in 2025, then plunged by 51.39% to $15.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $15.4 million, $31.7 million, and $8.5 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Immutep | 51.68 Mn | 51.68 Mn | - | 15.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.42 Mn |
| Dec 31, 2025 | 31.71 Mn |
| Jun 30, 2025 | 8.55 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Jun 30, 2024 | 7.95 Mn |
| Dec 31, 2023 | 5.30 Mn |
| Jun 30, 2023 | 7.34 Mn |
| Dec 31, 2022 | 6.12 Mn |
| Jun 30, 2022 | 5.80 Mn |
| Dec 31, 2021 | 8.25 Mn |
| Jun 30, 2021 | 6.74 Mn |
| Dec 31, 2020 | 11.54 Mn |
| Jun 30, 2020 | 8.72 Mn |
| Dec 31, 2019 | 10.20 Mn |
| Jun 30, 2019 | 11.32 Mn |
| Jun 30, 2018 | 10.20 Mn |
| Dec 31, 2017 | 7.63 Mn |
| Jun 30, 2017 | 6.33 Mn |
| Mar 31, 2017 | 5.22 Mn |
| Dec 31, 2016 | 6.90 Mn |